# OnCo record bladder-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/bladder-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "bladder-cancer-signalling" ;
  schema:name "Bladder cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05219"@en, "Bladder cancer"@en, "Urothelial carcinoma (KEGG)"@en ;
  schema:description "KEGG's bladder cancer map shows two routes: low-grade papillary tumours driven by FGFR3 or HRAS activating the MAPK relay, and high-grade invasive tumours that lose TP53 and RB1. Erdafitinib targets the first route; antibody-drug conjugates and PD-1 antibodies now anchor treatment of the second."@en ;
  schema:url <https://onco.cc/pathways/bladder-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05219>, <https://doi.org/10.1038/nrc3817> ;
  onco:related <https://onco.cc/pathways/fgfr-signalling/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/mdm2/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/erdafitinib/>, <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/disitamab-vedotin/> ;
  onco:pathways <https://onco.cc/pathways/fgfr-signalling/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-knowles-nat-rev-cancer/> .